Agile Therapeutics, Inc. (AGRX)
After hours:
- GlobeNewswire
Agile Therapeutics Provides Clinical Update on Twirla and Status of Pipeline Evaluation
FDA Agrees to Extended Milestones for Long-Term Twirla® Safety Study New Publication Supports Eventual Pursuit of AG200-15 Extended Regimen Development Program PRINCETON, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today provided an update on the Twirla® post-marketing studies and status of its ongoing evaluation of the Company’s pipeline. Twirla Post-Marketing Studies As part of Twirla’s approval, the United States Food and Drug
- GlobeNewswire
Agile Therapeutics Announces Distribution of Series C Preferred Stock to its Holders of Common Stock
PRINCETON, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series C Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 p.m. Eastern Time on February 6, 2023. The shares of Series C Preferred Stock will be distributed to such recipients at 5:0
- News Direct
Agile Therapeutics: This BioPharma Firm Is Nimbly Solving Unmet Needs For Women
By Johnny Rice, Benzinga
